FDA Approves Myriad’s myChoice® CDx Test to Help Identify Women Eligible for Treatment with Zejula® in Late-line Ovarian CancerGlobeNewsWire • 10/23/19
Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual MeetingGlobeNewsWire • 10/08/19
Myriad (MYGN) Up 5.9% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/12/19
Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer TreatmentGlobeNewsWire • 09/05/19
Myriad Genetics to Present at the 2019 Morgan Stanley Global Healthcare ConferenceGlobeNewsWire • 08/30/19
Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer PreventionGlobeNewsWire • 08/22/19
Why This Genetic-Testing Outlet Just Wiped Out Its 26% Breakout GainInvestors Business Daily • 08/14/19
Myriad Genetics stock plummets 39% after lower-than-expected earnings, FDA questionsMarket Watch • 08/14/19
Myriad Genetics, Inc. (MYGN) CEO Mark Capone on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/14/19